Phase III Trial in Treatment-Naïve Chronic Lymphocytic Leukemia Promises Valuable New Therapeutic Option

Large Heart Failure Studies Challenge Definition of Reduced Heart Failure

Novel JAK Inhibitor Shows Efficacy over 48 Weeks of Treatment for Long-Term Control of Rheumatoid Arthritis

New Therapy for Anemia Promises to Expand Options in Chronic Kidney Disease

FLAURA Trial: Survival Benefit Confirmed for Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Advanced NSCLC

Biologics for Challenging Asthma: New Perspective from Large Sets of Real-world Data

New Long-term Data Supports Early Intensive Therapy in RRMS patients

THEMIS-PCI: Potent Dual Antiplatelet Regimen Found Beneficial in Diabetic Patients with CAD and History of PCI

For Stroke Prevention in Patients with Atrial Fibrillation Undergoing PCI, Double Antiplatelet Therapy Found to be Safe

Landmark DAPA-HF Trial: New Approach to Treatment of Heart Failure

Clarifying the Heart Failure Story: Data from PARAGON-HF, EVALUATE-HF, and PROVE-HF

Phase 3 Data with New JAK Inhibitor in Rheumatoid Arthritis Predicts Evolving Sequence of Therapies